Fig. 3From: Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysisAll-cause HCRU during the 12-month follow-up period. ER emergency department/room, ICU intensive care unit, OI opportunistic infection. *Significant at P < .05Back to article page